Age Related Macular Degeneration Clinical Trial
Official title:
The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker
Aims of the trial: Establishing the profile of the growth factors and other mediators of
angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in
vitrectomized eyes), in the 2 most frequent proliferative retinopathies - diabetic
proliferative retinopathy (PDR) and exudative age related macular degeneration (AMD).
Following up the dynamic of this profile before and after intravitreal administration of
Bevacizumab (Avastin) as an anti-VEGF blocker.
Materials: The research will be conducted on the following categories of patients groups:
- nondiabetic patients without AMD or any other diagnosed proliferative ocular disease
(controls)
- patients with age related macular degeneration (AMD groups) before and after
intravitreal injections with Avastin
- diabetic patients with different types of diabetic retinopathy, before and after
intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids
will be collected from each group of patients. 10 growth factors and other 10 cytokines
will be determined in the ocular fluids samples.
Results: The results from the biochemical measurements will be statistically interpreted in
order to obtain conclusions for the clinical practice.
Conclusions: The conclusions of this trial will be used exclusively for research
publications and communications, as well as for clinical practice.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
| Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
| Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
| Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
| Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
| Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
| Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
| Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
| Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
| Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
| Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
| Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
| Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
| Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
| Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
| Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 | |
| Completed |
NCT00358345 -
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
|
Phase 4 |